GERON CORP (GERN)
$1.51-$0.02 (-1.31%) Today
Latest GERN Insider Trades
Michelle Robertson - OfficerOpen-market sale$19K
Michelle Robertson - Officer
John F. McDonaldGeron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 1 | 6,103 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
20 Form 4 filings on record, the earliest from Oct 1, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Robert J. Spiegel | Grant or award | Common Stock | 6,103 | $1.28 | $8K | |
| Robert J. Spiegel | Grant or award | Stock Option (right to buy) | 220,000 | $0.00 | - | |
| Elizabeth G. O'Farrell | Grant or award | Stock Option (right to buy) | 220,000 | $0.00 | - | |
| Susan Molineaux | Grant or award | Stock Option (right to buy) | 220,000 | $0.00 | - | |
| John F. McDonald | Grant or award | Stock Option (right to buy) | 220,000 | $0.00 | - | |
| Dawn Carter Bir | Grant or award | Stock Option (right to buy) | 220,000 | $0.00 | - | |
| Timothy Williams - Officer | Grant or award | Stock Option (Right to Buy) | 2,500,000 | $0.00 | - | |
| Robert J. Spiegel | Grant or award | Common Stock | 5,243 | $1.49 | $8K | |
 Constantine Chinoporos | Grant or award | Stock Option (Right to Buy) | 270,000 | $0.00 | - | |
| Patricia S. Andrews | Grant or award | Stock Option (Right to Buy) | 270,000 | $0.00 | - | |
| Joseph Eid - Officer | Grant or award | Stock Option (Right to Buy) | 2,220,000 | $0.00 | - | |
| Michelle Robertson - Officer | Option exercise | Common Stock | 27,500 | $0.00 | - | |
| Michelle Robertson - Officer | Open-market sale | Common Stock | 9,855 | $1.94 | $19K | |
| Michelle Robertson - Officer | Grant or award | Stock Option (Right to Buy) | 1,660,000 | $0.00 | - | |
| Michelle Robertson - Officer | Option exercise | Restricted Stock Units | 27,500 | $0.00 | - | |
| Ahmed Elnawawi - Officer | Grant or award | Stock Option (right to buy) | 3,000,000 | $0.00 | - | |
| Robert J. Spiegel - Director | Grant or award | Common Stock | 5,702 | $1.37 | $8K | |
| Harout Semerjian - Officer | Grant or award | Stock Option (right to buy) | 7,000,000 | $0.00 | - | |
| Harout Semerjian - Officer | Grant or award | Stock Option (right to buy) | 4,000,000 | $0.00 | - | |
| Robert J. Spiegel - Director | Grant or award | Common Stock | 5,540 | $1.41 | $8K | |
| V. Bryan Lawlis - Director | Grant or award | Stock Option (right to buy) | 180,000 | $0.00 | - | |
| V. Bryan Lawlis - Director | Open-market purchase | Common Stock | 13,300 | $1.18 | $16K | |
| Joseph Eid - Officer | Grant or award | Stock Option (right to buy) | 2,500,000 | $0.00 | - | |
| Robert J. Spiegel | Grant or award | Common Stock | 1,767 | $0.00 | - |
GERON CORP (GERN) had 1 insider filing in the last 90 days, with the most recent on 2026-07-01. The full record for GERN runs to 20 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of GERN were filed in the last 90 days. 1 purchase is on record for this company.
No insider sales of GERN were filed in the last 90 days. 1 sale is on record for this company.
This page tracks GERN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add GERN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
